您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > MSC-4106
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MSC-4106
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MSC-4106图片
CAS NO:2738542-58-8
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议

产品介绍
MSC-4106 是一种具有口服活性的 YAP/TAZ-TEAD 抑制剂。 MSC-4106 阻断 TEAD1 和 TEAD3 的 auto-palmitoylation,对 NCI-H226 异种移植瘤模型具有抑制作用。
Cas No.2738542-58-8
分子式C18H12F3N3O2
分子量359.3
溶解度DMSO : 250 mg/mL (695.80 mM; Need ultrasonic)
储存条件Store at -20°C, away from moisture
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

MSC-4106 is an orally active and potent inhibitor ofYAP/TAZ-TEAD. MSC-4106 inhibitsTEAD1orTEAD3auto-palmitoylation and shows inhibitory effect on NCI-H226 tumor xenograft model[1].

MSC-4106 (10 μM, 24 h) inhibited SK-HEP-1 reporter and NCI-266 cell viability with IC50values of 4 nM and 14 nM, respectively[1].
MSC-4106 (10 μM, 6 h) crystallizes in the P-site of TEAD1, and against TEAD1 or TEAD3 palmitoylation in TEAD-Overexpressing HEK293 Cells by 97.3% and 75.9%, respectively[1].
MSC-4106 (10 μM, 4 d) targets TEAD indicated by a reduction in viability of NCI-H226 cells[1].

Cell Viability Assay[1]

Cell Line:NCI-H226 (YAP dependent); SW620 YAP/TAZ KO (Yap-independent) cells
Concentration:0, 3, 6, 9, 12, 15, 18, 21, 24, 26, 30 μM
Incubation Time:96 hours
Result:Showed inhibitory effect to NCI-H226 and general cytotoxic to SW620 (IC50>30 μM).

Immunofluorescence[1]

Cell Line:SK-HEP-1
Concentration:0, 3, 6, 9, 12, 15, 18, 21, 24, 26, 30 μM
Incubation Time:24 hours
Result:Inhibited YAP-TEAD interation.

MSC-4106 (100 mg/kg/d; p.o.; 7 d) displays anti-tumor effect with controlled tumor volume and good tolerability with stable body weight in mice[1].
MSC-4106 (1, 5, 100 mg/kg/d; p.o.; 0-72 h) down-regulates Cyr61 (cysteine-rich angiogenic inducer 61) expression, the TEAD-regulated target gene, in tumor lysates at all time points at 100 mg/kg and 24 h at 5 mg/kg[1].
Pharmacokinetics (PK) profile in different species[1]

ParameterMouseRatDog
Cl (l/h/kg)0.20.70.05
PO t1/2(h)45403.6
PO AUC (μg•h/mL)451033
Vss(L/kg)250.3
F (%)>908018
Note: PO studies were performed at10 mg/kg; MSC-4106 was formulated in 20% Kleptose in 50 mM PBS at pH 7.4.

Animal Model:NCI-H226 xenograft model in H2d Rag2 female mice (9-week-old)[1]
Dosage:5, 100 mg/kg
Administration:Oral gavage; once daily; 32 days
Result:Resulted tumor growth controlled with 5 mg/kg while regressed with 100 mg/kg dosing after 32 treatment days.